New mRNA bird flu vaccine enters human testing
NCT ID NCT07019883
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new mRNA vaccine designed to protect against avian influenza (bird flu) in 80 healthy adults aged 18-49. The vaccine uses mRNA technology to teach the body to recognize and fight the H5 flu virus. The main goal is to check the vaccine's safety and see how well it triggers an immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AVIAN INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-3411, United States
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27703, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-0011, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.